TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00651664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib (MLN8237) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib (MLN8237) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib (MLN8237) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib (MLN8237) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib (MLN8237) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib (MLN8237) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib (MLN8237) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib (MLN8237) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib (MLN8237) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib (MLN8237) capsules
Study: NCT02998073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop, Now and Plan
Description: SNAP program was developed to target justice-involved youth (6 years and older) who have problems with aggression, CD, and/or gang affiliation. SNAP focuses on engaging youth in interesting and creative learning modules by providing real life scenarios designed to improve self-control, impulsive behaviors, decision-making skills, and pro-social skills. SNAP treatment is delivered over a 13-week period.
Study: NCT01895972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod
Study: NCT04041362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421
Description: Monoclonal antibody by IV infusion plus standard ART

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART)
Description: Standard ART

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral Therapy (ART)
Description: Standard ART
Study: NCT03483285

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: storz
Description: storz videolaryngoscope
Study: NCT04518878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Fixed dose of eltrombopag oral 25mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
Study: NCT02859792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole capsules (25 or 50 mg) will be administered in the four dose level groups (i.e. 25 mg bid; 50 mg bid; 75 mg bid; 100 mg bid).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules 25 or 50 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Samples
Description: v1;v2;v3;v4

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood Samples
Description: v1;v2;v3;v4
Study: NCT02069782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visiting
Description: Home visits are used to assess family needs, provide support and education, and make referrals to relevant community services. The goals of the programs are to improve child health and development, promote positive parenting, prevent child maltreatment, improve maternal and child health, and increasing parental self-sufficiency.
Study: NCT03942458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicagrel 6mg
Description: Vicagrel 24mg loading followed by 6mg/day for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Clopidogrel 300mg loading followed by 75mg/day for 6 days
Study: NCT02640677

Intervention type: BIOLOGICAL
Intervention: 4CMenB
Description: This study is strictly observational; Administration of BEXSERO, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
Study: NCT05037045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Description: GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM
Study: NCT03206203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by vein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03948568

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine Therapy and Radiotherapy
Description: Endocrine therapy and radiotherapy administered either concurrently or sequentially

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine Therapy and Radiotherapy
Description: Endocrine therapy and radiotherapy administered either concurrently or sequentially
Study: NCT06231862

Intervention type: DIAGNOSTIC_TEST
Intervention: SeptiCyte (various)
Description: mRNA expression scores

Intervention type: DIAGNOSTIC_TEST
Intervention: SeptiCyte (various)
Description: mRNA expression scores

Intervention type: DIAGNOSTIC_TEST
Intervention: SeptiCyte (various)
Description: mRNA expression scores
Study: NCT02017340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilvadipine
Description: 8mg of Nilvadipine taken once a day at lunch time for 78 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8mg Placebo tablet taken once a day at lunch time for 78 weeks
Study: NCT00930293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)
Description: 16 weekly IPT-PS sessions, each lasting approximately 45 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Supportive Psychotherapy (BSP)
Description: 16 weekly BPS sessions, each lasting approximately 45 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram hydrobromide
Description: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram hydrobromide
Description: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
Study: NCT03280602

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension band wiring (TBW)
Description: 2 x K-wire fixation (1.6 mm) and wire cerclage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension band wiring (TBW)
Description: 2 x K-wire fixation (1.6 mm) and wire cerclage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plate fixation
Description: Olecranon fractures in this arm are fixed with Synthes´ VA-LCP Olecranon Plates 2.7/3.5.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plate fixation
Description: Olecranon fractures in this arm are fixed with Synthes´ VA-LCP Olecranon Plates 2.7/3.5.
Study: NCT04429217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate post-operative complete weight-bearing after surgery
Description: Patients randomized to the experimental post-operative rehabilitation intervention will undergo to immediate complete weight-bearing starting immediately after surgery. Immediate complete weight-bearing consists in the possibility to undergo all the everyday activities without limiting weight-bearing and without the use of walking aids.~During the rehabilitation period, patients will wear an ankle brace (VACOankle® OPED); this will ensure the safety of the early recovery phases, protecting from dangerous movements while allowing the mobilization in the healthy range of movement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed weight-bearing for 6 weeks after surgery
Description: Patients randomized to the control post-operative rehabilitation intervention will undergo to delayed weight-bearing starting at 6-weeks post-operatively. Delayed weight-bearing consists in the limitation of the weight-bearing to 20-30% of patient's total weight using crutches for the first 6 weeks after surgery.~During the rehabilitation period, patients will wear an ankle brace (VACOankle® OPED).
Study: NCT01280981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
Study: NCT00508378

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview regarding side-effects of chemotherapy, 30-45 minutes.
Study: NCT01630161

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (\<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Relapse Prevention for Cancer Patients (SRP-CaP)
Description: The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One).
Study: NCT00508378

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Quality of life survey and symptom assessment questionnaire, 15 minutes.
Study: NCT04112043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking Exercise
Description: Participants randomized to this intervention 3 days/week of supervised, center-based walking exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking Exercise
Description: Participants randomized to this intervention 3 days/week of supervised, center-based walking exercise.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside (NR)
Description: Participants randomized to this intervention will receive 1,000 mg/day of NR.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside (NR)
Description: Participants randomized to this intervention will receive 1,000 mg/day of NR.
Study: NCT00595855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trabeculectomy
Description: Cairns-like trabeculectomy, limbus based, with 5_FU supplementation and argon laser suturelysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deep sclerectomy
Description: deep sclerectomy with no implant and no sutures to the superficial flap, limbus based with suppplementation of FU (if needed)
Study: NCT01344824

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: bevacizumab
Description: 15 mg/kg once per 21 day cycle (up to 4 cycles).

Intervention type: DRUG
Group type: OTHER
Intervention: carboplatin
Description: Area Under the Curve (AUC)=6, once every 21 day cycle (up to 4 cycles)

Intervention type: DRUG
Group type: OTHER
Intervention: erlotinib hydrochloride
Description: 150mg, daily for 21 day cycle (up to 4 cycles)

Intervention type: DRUG
Group type: OTHER
Intervention: pemetrexed disodium
Description: 500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)
Study: NCT00322309

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for days 1-4 Placebo for days 5-9 Placebo for days10-78 Placebo for days 79-81 Placebo for days 82-84

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Days 1-4 15mg Days 5-9 30 mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg
Study: NCT03259425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab at a dose of 240 mg given as an IV infusion starting on day 0. It will be given every 14 days for a total of 7 infusions; Then participant will undergo surgery. Nivolumab will then be administered at a flat dose of 480 mg IV every 28 days for up to one year.
Study: NCT04468438

Intervention type: DIAGNOSTIC_TEST
Intervention: serum estrogen and urinary albumin creatinine ratio
Description: serum estrogen and urinary albumin creatinine ratio

Intervention type: DIAGNOSTIC_TEST
Intervention: serum estrogen and urinary albumin creatinine ratio
Description: serum estrogen and urinary albumin creatinine ratio
Study: NCT03259425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF10
Description: 1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.
Study: NCT00673972

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: gastric scintigraphy
Description: All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.~Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: gastric scintigraphy
Description: All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.~Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window.
Study: NCT01514292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring of glucose levels (Dexcom)
Description: Manipulation of glucose levels during multiple clinic days. Achieved through diet, exercise and insulin regimen defined in protocol.Evaluation of CGM performance characteristics in reference to a laboratory standard.
Study: NCT04305457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the subject.
Study: NCT02432612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Sativex is supplied as a liquid containing 27 mg/mL Δ9-tetrahydrocannabinol (THC) and 25 mg/mL Cannabidiol (CBD) plus peppermint flavoring. Each 100 µL actuation of the pump-action spray delivers 100 µL 27 mg THC and 25 mg CBD.
Study: NCT03436628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyT1DHero
Description: A mobile phone application
Study: NCT04528095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Clozapine 400 \~ 600mg/d or plasma concentration \>350ng/ml Amisulpride 200-800mg/d Gingke biloba 120-360mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Clozapine 400 \~ 600mg/d or plasma concentration \>350ng/ml Amisulpride 200-800mg/d Gingke biloba 120-360mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Clozapine 400 \~ 600mg/d or plasma concentration \>350ng/ml Amisulpride 200-800mg/d Gingke biloba 120-360mg/d

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MECT
Description: MECT:The treatment lasted for 4 months,16 times in total MST:The treatment lasted for 4 months,16 times in total

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MECT
Description: MECT:The treatment lasted for 4 months,16 times in total MST:The treatment lasted for 4 months,16 times in total

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS
Description: Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
Study: NCT04741360

Intervention type: OTHER
Group type: OTHER
Intervention: Modified Story Memory Technique
Description: 10-session computerized program to improve new learning and memory

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Story Memory Technique
Description: 10-session computerized program to improve new learning and memory
Study: NCT03867591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastro-AD®
Description: The product under study is Gastro-AD® fermented soy powder in the form of orodispersible flavored powder packed in non-transparent sachets.~Content: 1 g of Gastro-AD® powder per sachet + flavoring agents.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product will have very similar appearance, color, texture and taste as the Gastro-AD® flavored sachet. The placebo sachets contain the respective amount of maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
Study: NCT01441271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileal diversion and lavage
Description: The surgical approach involves an attempted laparoscopic creation of a loop ileostomy after visually assessing the colon to assure viability. If the loop is unable to be safely performed laparoscopically an open loop ileostomy will be performed. Intraoperatively, 8 liters of warmed polyethylene glycol 3350/electrolyte solution \[GoLytely®; Braintree Laboratories\] will be infused into the colon via the ileostomy and collected via a rectal drainage tube. Post-operatively, the patients will receive antegrade vancomycin flushes \[500 mg in 500 ml of Lactated Ringers; q8 hours for duration of 10 days\] via a Malecot catheter \[24 French\] left in the efferent limb of the ileostomy (Figure 1). Additionally patients will be continued on intravenous metronidazole \[500mg q8 hours\] for 10 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total abdominal colectomy
Description: The surgical approach of the colon in a total abdominal colectomy involves a midline incision. The complete colon in the abdomen (from ileum to rectum) will be removed and an end ileostomy is performed.
Study: NCT03818958

Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling

Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling

Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling

Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling
Study: NCT02277652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Miller Laryngoscope
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Miller Laryngoscope
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Miller Laryngoscope
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Miller Laryngoscope
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Miller Laryngoscope
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Miller Laryngoscope
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bonfils intubation fibrescope
Description: Optical laryngoscopy
Study: NCT04253483

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Rate Brachytherapy
Description: Undergo HDR
Study: NCT02277652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bonfils intubation fibrescope
Description: Optical laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bonfils intubation fibrescope
Description: Optical laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bonfils intubation fibrescope
Description: Optical laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bonfils intubation fibrescope
Description: Optical laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bonfils intubation fibrescope
Description: Optical laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The GlideScope Ranger
Description: Videolaryngoscopy